RPG Life Sciences plans ₹500 crore push into manufacturing and APIs
In short
RPG Life Sciences said it plans to spend ₹500 crore in the next 12 months to boost manufacturing and API work. The company said it already used ₹200 crore on acquisitions and has ₹700 crore of committed capital.
This matters because the drug maker is expanding its capacity and buying assets to support growth. The report does not name the deals or say which plants or products will be added.
What the reporting says
RPG Life Sciences said it plans to deploy ₹500 crore over the next 12 months to strengthen manufacturing and API capabilities through strategic acquisitions. Managing Director Ashok Nair said the company is in an expansion phase backed by a committed ₹700 crore capital infusion, with ₹200 crore already used for acquisitions. The immediate effect is a larger investment program, while the reporting does not identify the targets or exact projects.
Why it matters
RPG Life Sciences said it will deploy ₹500 crore over the next 12 months to strengthen manufacturing and API capabilities through strategic acquisitions. Managing Director Ashok Nair said the company is in a major expansion phase and has a committed capital infusion of ₹700 crore, with ₹200 crore already spent on acquisitions. The reporting does not name acquisition targets, project locations or expected returns.